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Abstract 
Companies regard innovation as a central element of their business. However, as not all 
innovation types are the same, the central question is: should their announcements bring 
about the same effect on performance? This article analyses potential differences in firm 
value derived from the innovation-type announcements ‘R&D’, ‘product’ and ‘process’, 
made by intensive news-generating firms such as biotech companies. The empirical 
application shows a significantly positive reaction to innovation announcements, with 
the prospect of future innovation (‘R&D’ investment announcements) having greater 
impact on firm value than ‘product’ and ‘process’ innovations. Firm experience also 
acts as a moderator in this innovation-performance relationship, which is particularly 
relevant for entrepreneurs, who need to develop and send credible signals indicating the 
value of the firm's intangible assets to the market. 
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1. INTRODUCTION 
Innovation is a crucial element in today’s firm development, productivity and 
competitiveness (Máñez et al., 2005; Fetterhoff and Voelkel, 2006; Wolff, 2006; Hahn, 
2010; Delgado-Verde et al., 2011; Damijan et al., 2012; Martinez-Senra et al., 2013); 
still, it is not unusual to find innovating firms that often fail to obtain economic returns 
from their innovative activities (Su et al., 2013). In this article, we focus on 
biotechnology firms, for which innovation is a particularly critical cornerstone (Casper 
et al., 1999; Cooke, 2001; Gertler and Levitte, 2005; Trippl and Tödtling, 2007), by 
analysing three types of innovation announcements (R&D, process and product 
innovation). 
According to the United Nations, biotechnology consists of ‘any technological 
application that uses biological systems, living organisms, or derivatives thereof, to 
make or modify products or processes for specific use’. Consequently, ongoing 
innovation is, per se, a central, core element for biotechnology and for the firms 
involved in this industry (McMillan et al., 2000). Therefore, innovation defined as 
something original, new, and important that breaks in to a market or society (Frankelius, 
2009) has special relevance in this industry. 
In general terms, the positive relationship between innovation and performance 
has been widely shown (Naranjo-Gil, 2009; Bayona-Sáez and García-Marco, 2010; 
Yam et al., 2011; Trigo and Vence, 2012), due to the higher probability of survival 
(Hall and Williams, 2008), higher competitive edge gained (Victorino et al., 2005), the 
differentiation reached (Walsh et al., 2008) and cost reductions attained (Chan et al., 
1998). This positive relationship between innovation and performance has been found 
by using different indicators of firms’ innovation capabilities, such as R&D (Toivanen 
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et al., 2002; Eberhart et al., 2004; Hall and Oriani, 2006) or new products (Angelmar, 
1990; Chaney and Devinney, 1992; Geroski et al., 1993; Srinavasan et al., 2009).  
However, not all innovations are equal or have the same implications (Amable 
and Palombarini, 1998; Tether, 2001; Zach and Fesenmaier, 2009), which is why 
Hjalager (2010) claims that more research is needed to evaluate the potential 
differentiated effect of innovation types on performance. That’s why this article 
attempts to analyse potential differences in the innovation-type announcements made in 
terms of R&D, product and process. While discussed more in detail later, in general 
terms, research & development must increase the firm’s sales (Natsukawa et al., 2013; 
Ma et al., 2014), product innovation implies an improvement in a product which is 
expected to generate greater turnover (Guo et al., 2013; Høyvarde and Pohjola, 2013; Su 
et al., 2013), and process innovation involves an improved production method leading 
to efficiency enhancement (Barge-Gil et al., 2011).  
Moreover, the literature shows that the firm’s experience exerts a significant 
impact. Sahra (1996) indicates that new ventures -eight years or younger-, ‘play a major 
role in the development of an emerging, high-technology industry’. Accordingly, along 
with this non-linear effect, and considering that entrepreneurs need to develop and send 
credible signals indicating the value of a recently created idea, we examine whether 
experience moderates the effect of innovation types, in such a way that managers can 
detect the best decisions in terms of innovation depending on the age of the firm. 
With the objective of analyzing potential differences in firm value derived from 
the innovation-type announcements ‘R&D’, ‘product’ and ‘process’, made by biotech 
companies, we first detect all the innovations announced by any biotechnological 
company ever trading in the Spanish market between 1994 and 2008 (the Factiva 
database is used for this purpose), leading to 26 innovation announcements. The 
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subsequent sections of the article are arranged as follows: Section 2 reviews these types 
of innovation and proposes several explanatory variables of firm value; Section 3 
outlines the method and data employed; Section 4 describes the results; and Section 5 
presents the conclusions. 
Insert Figure 1 about here 
2. INNOVATION IN BIOTECHNOLOGICAL COMPANIES 
On July 28, 2011, The Washington Post published the ‘top 10 most innovative 
biotech companies’. While in other industries other criteria are used, for biotechnology-
related firms, their innovation capability is employed to establish a definite ranking. 
Certainly, innovation is an essential decision area for them, and as such, they try to keep 
the public aware of their innovative actions. But, how do they let the market know of 
their progress in this field? The communication strategy, which is critical these days 
(Rose et al., 2007), revolves around R&D announcements, product and process 
innovations (see Figure 1). 
Regarding research & development, this term is defined by the OECD (1993) as 
‘research and experimental development comprised of creative work undertaken on a 
systematic basis in order to increase the stock of knowledge, (…) and the use of this 
stock of knowledge to devise new applications’. Accordingly, it may or may not lead to 
a practical application, but in the end, the aim of R&D should be focused on the 
creation of innovations for commercial exploitation; therefore, R&D should eventually 
lead to an increase in sales. 
Product innovation is the ‘introduction of a good or service that is new or 
significantly improved with respect to its characteristics or intended uses. This includes 
significant improvements in technical specifications, components and materials, 
incorporated software, user friendliness or other functional characteristics. Product 
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innovations can utilize new knowledge or technologies, or can be based on new uses or 
combinations of existing knowledge or technologies’ (Oslo Manual, 2005). Note that 
the notion of ‘product’ implies a complex process influenced by technology 
development, shifts in customer needs and wants, length of product life cycles and 
degree of global competition (Gunday et al., 2011), leading to different innovation 
persistence across types of product innovation (Høyvarde and Pohjola, 2013). As Akova 
et al. (1998) indicates, it implicitly leads to the observation of a strong interaction with 
all the decision areas within the firm and the firm with its customers and suppliers.  
Process innovation is the ‘implementation of a new or significantly improved 
production or delivery method. This includes significant changes in techniques, 
equipment and/or software. Process innovations can be intended to decrease unit costs 
of production or delivery, to increase quality, or to produce or deliver new or 
significantly improved products’ (Oslo Manual, 2005). Note that, according to Gunday 
et al. (2011), process innovations are linked to technological developments. All these 
three types of innovations come with a cost that is expected to be subsequently paid-off. 
In fact, note that the emphasis of process innovation is made on its cost-cutting nature 
(Fagerberg et al., 2004); that is, a basic objective of process innovation is to reduce 
costs irrespectively of the expected demand. 
Therefore, the following hypotheses are proposed: 
H.1a.: R&D leads to an increase in firm value. 
H.1b.: Product innovation leads to an increase in firm value. 
H.1c.: Process innovation lead to an increase in firm value. 
At this point, the key question is which innovation type is expected to have a 
greater impact on firm value (see Figure 1). No universal statement can be established, 
since there are differences both between and within innovation types. A priori, no 
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ranking among them can be set as it all depends on the amount of costs and sales 
expected. So far, abstract affirmations have been stated such as ‘process innovations are 
more influential than product innovations’ (Hjalager, 2002; Weidenfeld et al. 2010), 
but, still, it is not straightforward to make general assertions on this issue. At most, one 
could argue that R&D is more expectation-dependent, as they are future promises of 
tangible items; and product and process innovations, on the contrary, are real 
materializations of past R&D investments. On this account, this different approach 
might lead to distinct perceptions of the effect on performance. Consequently, we 
propose the following hypotheses: 
H.2a.: R&D (as a promise of future tangible items) has an effect on firm value 
which is different from product innovations (which is already tangible). 
H.2b.: R&D (as a promise of future tangible items) has an effect on firm value 
which is different from process innovations (which is already tangible). 
 
It is important to consider the firm experience (firm age) as a moderator of the 
three types of announcements. The effect of firm experience on innovation has only 
been approached recently, despite its paramount importance for entrepreneurs that need 
to develop and send credible signals indicating the value of the firm's intangible assets 
to the market (Deeds et al., 1997). Sorensen and Stuart (2000) and Huergo and 
Jaumandreu (2004) conclude, in general terms, that as firms accumulate experience, 
their innovation quality changes. It has only been as recently as 2008 that 
Balasubramanian and Lee (2008) confronted the two mainstream opposing theories 
posited to explain the age-innovation relationship. On the one hand, learning-by-doing 
can be applied to innovation, so that the firm’s innovative abilities might be enhanced as 
it increasingly acquires more experience; and on the other hand, organizational inertia 
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can take over: the organizational capabilities learned over the years certainly bring 
about positive returns, but they are not easy to create and, more importantly, they might 
imply high costs. Therefore, if the firm has incurred such costly investment, it will have 
quite a low willingness to get involved in major adjustments to its already-created-and-
costly-adjusted capabilities. In their study, Balasubramanian and Lee (2008) find that 
‘each additional year reduces the impact of a 10% increase in R&D intensity on the 
firm's market value by over 3%’: as the firms accumulate experience, their net 
adjustment costs rise. In the face of this evidence, the signal created by an innovation 
announcement should be more positively impacting on younger firms, as riskier and 
more daring -and consequently, more profitable- innovative actions that could imply 
further re-adjustments to the firm’s capabilities are more likely to occur among younger 
firms. Therefore, we propose in hypothesis 3 that: 
H.3.: Firm’s experience exerts a moderator effect on the impact of innovation on 
firm value. 
Finally, we add two control variables to the proposed relationships in Figure 1 
(intangible character and growth): i) Intangible character: Most of the literature on 
innovation has focused on manufacturing, but there are differential characteristics on the 
part of services that are necessary to be considered in innovation research (Camacho 
and Rodriguez, 2008; Criscuolo et al., 2012; Zach, 2012; Tussyadiah, 2013). In fact, 
Tether (2005) empirically finds, in his analysis of 3,014 European firms found in the 
Innobarometer Dataset, that service companies have a different innovation orientation 
from manufacturers. In particular, while manufacturers carry out innovation changes in 
a more occasional discrete step-wise way, service companies are more used to 
undertaking continuous changes, which are mainly oriented to improving ‘soft’ 
capabilities (e.g. skills of their workforce or co-operation practices with suppliers and 
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customers) (Tether, 2005). Consequently, on the one hand, ‘changing continuously’ 
leads service companies to consider adaptation and adjustment as the norm; and on the 
other hand, as they are more inclined to organizational innovations (more than to the 
development of new products and new processes) (Tether, 2005), the concomitant 
changes derived from these innovations should be less costly, both in monetary terms 
and in re-adjustments efforts. And ii) Growth: The relationship between innovation and 
growth is a two-way street: innovation is essential for growth (Bishop et al., 2009), and 
growth is critical for innovation (Mansury and Love, 2008; Mason et al., 2009). A 
priori, the higher the firm’s growth, the greater the impact of an innovation 
announcement on firm value. Given that the company has grown, it is expected that its 
capacity to keep on innovating will continue in the future (Mason et al., 2009), 
enhancing its future perspectives. This argument is in line with the discussion of 
Blundell et al. (1999) about the relationship between innovation and market share. They 
find that the effect of innovation on market value is higher for companies with a higher 
market share, suggesting that leading firms tend to bring about innovations that are 
intrinsically of higher quality. Freel (2000) points out that ‘although it is not necessarily 
true that innovators are more likely to grow, nevertheless innovators are likely to grow 
more’.  
3. METHOD AND DATA 
The method followed to test the stated variables is as follows: to test the effect of 
innovation announcement on the market value (H1), we rely on the event study 
methodology; and for innovation types (H2) and the moderator effect of experience 
(H3) (along with the control variables), we employ regression analysis. 
Event study. The use of the event-study method allows us to measure the 
potential existence of abnormal returns derived from the stock market reaction to 
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innovation announcements. In this context, Park and Kim (1997) indicate that the firm's 
stock price reflects the market judgment of the likely payoffs from entrepreneurial 
activities, so it might show a distinction depending upon the firm’s experience. 
According to McWilliams and Siegel (1997), we first detect all the innovations 
announced by any biotechnological company ever trading in the Spanish market 
between 1994 and 2008 (the Factiva database is used for this purpose). The event day is 
defined as the first day in which the news is released. The search detects 31 innovation 
items belonging to the six biotechnological firms that trade in the Spanish Stock 
Exchange with an average number of five innovations each. Note that the focus is on the 
announcement, which turns out to be the relevant data for the analysis. Next, we look 
for possible confounding news published close to the announcement day, such as 
takeover bids, profit announcements, dividend declarations, split announcements, 
complaints, claims, government contracts, court cases, or labor disputes, etc. 
Accordingly, 5 announcements appear to have confounding effects, so we are left with 
26 news items. Finally, we collect data on market measures of performance: daily 
returns on the shares of the 26 innovation announcements during the period January 3, 
1994 to 31 December 30, 2008, a temporal period defined by the availability of daily 
stock market information. These daily returns are adjusted with dividends, subscription 
rights and splits. The returns on the share price of a company i on day t (Rit) are 
expressed as:  
Rit=αi+βiRmt+εit  (1) 
where Rmt=returns on the market portfolio on day t (this study uses the IBEX-35, a 
representative index of the Spanish Stock Market; the information is obtained from the 
Stock Exchange Society); αi=returns on the shares of company i independent of those of 
the market; βi= sensitivity of returns on the share i to variations in market returns; and 
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εit= error term. The estimation of equation (1) allows us to calculate daily abnormal 
returns (AR) for a company i announcement:  
ARit=Rit-(ai+biRmt)  (2) 
where ai and bi are the estimations of the regressions (1) for a period T before the event. 
It is important to note that the characteristic kurtosis and heteroskedasticity in the error 
term of equation (1), which have been detected in various empirical applications, would 
lead to defective estimates. For this reason, this study estimates an autoregressive 
conditional heteroskedasticity model, GARCH(1,1), whose main purpose is to model 
the conditional variance of the returns. Such models distinguish between unconditional 
variance, which is constant and stationary, and conditional variance, which is modified 
by the available information. Thus, the returns defined by means of this specification 
are obtained by assuming that  
εit= hit1/2ηit  and  εit/εit-1,εit-2,...∼N(0, hit) 
where ηit i.i.d. with E(ηit)=0  and  E(η2it)=1.  
In this context, hit is the conditional variance and is represented as  
hit=ci+λiε2it-1+γihit-1  (3) 
where ci, λi and γ i are parameters to be estimated. 
To confirm the results, we also estimate abnormal returns through the Theil 
nonparametric regression technique is used, according to the following process: i) sort 
the T pairs of (Rt, Rmt) in the estimation period in ascending order of the Rmt; ii) separate 
the data pairs into two groups based on the median, excluding the median pair if T is 
odd; iii) calculate a slope parameter β for each of the T/2 data pairs in each group by 
computing the expression  
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iv) Sort the calculated slope parameters in ascending order; v) estimate β with the 
median slope and compute the values of tαˆ  for all data pairs; and vi) estimate α with 
the median value of the tαˆ . 
To analyse the effect of a biotechnological company’s innovation announcement 
on its share price, this article tests the significance of its average abnormal returns in the 
event window (-1,+1) using the traditional test of Brown and Warner (1980). 
Regression analysis. To test the variables we rely on regression analysis, so that 
‘innovation types’ (PDIi=product innovation and PCIi=process innovation), 
‘experience’ (Expi), ‘growth’ (Gri) and ‘intangible character’ (Inti) are included as 
explanatory variables of ‘excess returns’ or ‘abnormal returns’ (ARi). Subscript i refers 
to the information of the company at the time of the innovation announcement i. The 
resulting regression is as follows 
iiiiiiiiiiii IntGrExpExpPCIExpPDIPCIPDIAR µδδδδδδδδ ++++++++= 87654321 (5) 
where µi is the error term. Note that to test the hypothesised moderating effect of 
experience, the variable Expi must also be included alone, together with the interaction 
term (Baron and Kenny, 1986). It means that experience not only can have a moderating 
effect on the relationship ‘abnormal returns−innovation type’, but also a direct effect on 
abnormal returns. Therefore, according to the terminology of Sharma et al. (1981), the 
variable ‘experience’ can behave as a ‘pure moderator’ (i.e., if it has only a moderating 
effect through its interaction with ‘innovation type’) or as ‘quasi-moderator’ (i.e., if it 
has both a moderating effect through its interaction with ‘innovation type’ and a direct 
effect in itself). 
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As The measurement of these explanatory variables in the regression analysis is 
as follows: Innovation types (R&D, product and process innovations) are measured 
through dummy variables (R&D is taken as the base alternative). Firm experience is 
measured by age. According to Balasubramanian and Lee (2008), firm age captures 
overall firm experience, as it can incorporate all the effects of learning processes and 
accumulated knowledge that can have an impact on innovation. For ‘intangible 
character’, a categorical variable is used, which takes value 1 if the firm includes service 
components and 0 if it is a pure manufacturer. Growth is calculated through the average 
annualised growth in turnover over the last three years prior to the announcement, 
defined as Growth=1/3·[ln(turnovert-1/ turnovert-3)]. For a summary, see Table 1. 
Insert Table 1 about here 
4. RESULTS 
Table 2 shows the estimation of the average abnormal returns of the 26 
announcements in the (-1+1) event window. The results obtained demonstrate that, on 
average, innovation announcements are associated with positive excess returns on the 
previous day; in particular, both estimation procedures lead the Brown and Warner test 
to present significant values on day -1. This means that, on average, firms announcing 
innovation activities undergo a minimum gain of 0.54% on the day before the 
announcement. This one-day advanced reaction seems plausible as innovation 
announcements of biotech companies might leak before formal, public releases. This result 
supports hypothesis 1 that R&D, product innovation and process innovation lead to an 
increase in firm value, which is in line with the extant literature (Bayona-Sáez and 
García-Marco, 2010; Yam et al., 2011; Trigo and Vence, 2012). 
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Insert Table 2 about here 
Once the abnormal returns are estimated and tested, we analyse whether the 
distinct innovation types have differentiated effects on these abnormal returns. Table 3 
shows the results of the regressions conducted. We estimate two equations, one with the 
Garch-generated abnormal returns and the other with the Theil-generated excess returns.  
As for the individual parameters, we find that the effect of ‘R&D’ is 
significantly greater than both ‘product’ and ‘process’ innovations’. These greater 
returns are confirmed in the two equations. Also, the chi-square test finds that there are 
no significant differences between ‘product’ and ‘process’ innovations in either 
equation (χ2=3.46; p>0.05 and χ2=2.15; p>0.05). These results suggest that the distinct 
character between ‘future promises of tangible items’ drive greater perceptions of 
performance than ‘already materialized product and process innovations’, supporting 
hypothesis 2 that R&D has a differentiated effect on firm value when compared to 
product and process innovations. 
Insert Table 3 about here 
As for the moderating effect of experience, we find that the innovation type 
effect is reversed as the firm gets older: for more experienced firms, the effects of 
‘product’ and ‘process’ innovation tend to exceed that of ‘R&D’ (as before, no 
differences exist between ‘product’ and ‘innovation’ in either equation [χ2=1.40; p>0.05 
and χ2=1.13; p>0.05]). This result is in line with hypothesis 3 that firm’s experience 
exerts a moderator effect on the impact of innovation on firm value. To be specific, 
according to Sharma et al.’s (1981) taxonomy, ‘experience’ appears to be a quasi-
moderator (rather than a pure moderator), as the variable itself has an effect on firm 
value; in particular, it is significantly negative, supporting the theory that innovation has 
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a higher effect on the firm value of younger companies. This result is in line with the 
evidence found by Balasubramanian and Lee (2008), on account of the riskier but more 
profitable innovative actions of younger firms. Table 4 presents these main results 
regarding the hypotheses tested: 
Insert Table 4 about here 
Finally, regarding the ‘intangible character’, it is significant in both equations, 
while ‘growth’ is not. The intangible character has a negative sign, which means that, 
there might be differential characteristics on the part of services that are necessary to be 
considered in innovation research, as they have a different innovation orientation 
(Camacho and Rodriguez, 2008; Tether, 2005). 
5. CONCLUSIONS 
Companies within the biotechnology industry regard innovation as a core 
activity. Therefore, implementing such activities is an essential decision area for them; 
furthermore, letting the market know about these activities is critical in terms of public 
relations strategies. The adequacy of right announcements helps them convey a specific 
image and, on this account, it is relevant to analyse potential differences in the 
innovation-type announcements. This is especially relevant for entrepreneurs, who need 
to develop and send credible signals indicating the value of the firm's intangible assets 
to the market, and this is even more relevant if we consider that new ventures and 
younger companies play a major role in the development of an emerging, high-
technology industry. This study shows that younger firms send these credible signals 
appropriately and better than older ones. 
The empirical application also finds a significant reaction when the innovation-
related information is released, showing that the prospect of future innovation (‘R&D’ 
investment announcements) has greater impact on firm value than ‘product’ and 
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‘process’ innovations. As stated, this effect is moderated by ‘experience’ in such a way 
that as the firm gets older, the latter innovations tend to increase the firm’s value greater 
than the former (even though, the total impact is still outperformed by ‘R&D’). 
Accordingly, implications for management revolve around the idea of properly 
communicating the right type of news. In the light of the results, expectations are a key 
element when it comes to firm value formation. Therefore, biotech companies must pay 
attention, not only to their new products and processes but also to their new ideas, 
contracts and all kind of potential activities that can lead to effective R&D activities.  
The finding that the biotech market value varies when the prospect of innovation 
activities is announced indicates that this measure can be regarded as appropriate to 
analyse this type of investments. The use of market value facilitates the analysis of the 
effect of innovation on performance by estimating unbiased market predictions on 
future profits. This technique employs a forward-looking firm performance that 
overcomes all the difficulties of the traditionally used backward-looking firm 
profitability, i.e., accounting measures. Specifically, once the innovation is announced, 
managers might observe the evolution of share prices to determine how valuable the 
news is perceived to be by the shareholders. If the shareholders’ perceptions of it are not 
as good as the managers would have expected, they may want to see whether this is due 
to a lack of information (or even to misinformation). If this were the case, a new flow of 
information should be released, in order to clarify the firm’s innovation. Also, finding 
that innovation has a positive impact on firm market value means that the market 
considers that an innovative company is a healthy firm. Therefore, any biotech company 
introducing innovations, no matter whether they are internal or external, should show 
that it is innovating all the time, by releasing information through a well-executed 
public relations program. For example, in the event of getting an innovation award, it 
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would represent a way of demonstrating that the decisions made on innovative issues 
have been correct. This can reduce agency conflicts and reinforce the trust shareholders 
have in the management team. In a time when uncertainty is the norm, showing that 
one’s decisions have been appropriate is not trivial. Ultimately, innovation can help the 
firm position itself in people’s minds. 
This fact, along with the outcome that these variations in biotech market value 
are contingent upon the type of innovation, suggests that, when a comprehensive 
examination is pursued, different types of innovations and distinct kinds of 
measurements should be employed. While innovation types are expected to lead to 
different results, the use of several performance measures (as firm value) might permit 
the identification of hidden effects that, otherwise, would not be easy to uncover. Note 
that, in the end, using distinct performance measures implies looking at the company 
from different perspectives; perspectives that represent facets that might be worth 
looking into them.  
Finally, the youth of a firm that sends innovation-related information seems to 
be captured by the market and, therefore, it is relevant information for venture 
capitalists. Firm value reflects higher increases derived from innovation announcements 
in younger firms than older due to the riskier but more profitable innovative actions of 
younger firms. Mistakenly or not, the market seems to have the perception that older 
firms are less adventurous and more reluctant to change. Accordingly, such firms 
should pay special attention to this fact and provide the market with extra information 
as to the scope and reach of their innovations. 
Regarding the study’s limitations, two shortcomings have to be considered: i) 
The small sample size used. It is true that existing empirical applications of the event 
study technique show that it might still be large enough to detect reactions in share 
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prices (Gomez, 2001), and that, according to the data collection process followed, it is 
guaranteed that the sample contains all the news items released during the study period, 
but the reduced sample certainly prevents us from making generalizations; and ii) 
Ideally, the appropriate test to find differences in the effects of ‘future promises’ (R&D) 
and ‘materialized promises’ (product and process innovations) should consider the 
string of investments, from the outset to the final output, in a specific item; that way, 
one could observe the variations in firm value both, at the time of announcing 
prospective research on an issue and at the time of producing tangible results. However, 
this is not always possible as, first, no specific information is always provided when 
general statements about R&D investments are announced, and second, even if it were 
provided, it would not be easy to determine a correlation between each new created item 
and each euro spent in R&D activities that lead to several brand-new items. 
For further research, several lines can be followed in order to provide a more 
comprehensive view of the relationship between innovation and biotech market value: 
1) The paper has used the Schumpeterian classification to identify differentiated effects 
in innovation types; nevertheless, the use of other taxonomies would offer a broader 
view in terms of academic perspectives (as it would permit the identification of the best 
explanatory classification) as well as in terms of management perspectives (as it would 
show decision-makers the best innovation types according to the taxonomy used). 2) A 
larger sample would permit the use of more potential explanatory factors. 3) The use of 
specific information on each innovation, especially in terms of costs incurred in the 
investment could shed more light on the specificities of every initiative; that is, knowing 
the cost invested in an innovation could determine how costly (per unit) the variations 
in market value are. 4) As market value has been shown to reflect innovation 
announcements, it is possible to analyze the effect of innovation-based competitive 
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reactions on the firm. In other words, as the market value captures the firm’s innovation 
strategy, it could be expected that it will reflect the competitor’s innovation strategy too. 
It would facilitate a rivalry analysis between actions and reactions based on innovation 
strategies. 5) With the advent of new technologies, other measurements of innovation 
impact can be used. If “twitter” were treated as a market where information is 
exchanged, and the number of “tweets” were considered as a measure of repercussion 
(or hype), it could be interesting to observe the expectations generated by an innovation 
announcement on a specific day. Paralleling the method employed in this article, it 
would imply observing whether the amount of “exchanged information” (tweets) 
derived from a firm’s release of news on a given day is abnormally superior to the 
quantity of “exchanged information” in a normal day, and whether and how many good 
things are published. 
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Figure 1. Innovation types and firm value 
Innovation 
types
Product
Innovation
R&D
Process
Innovation
Firm value
Control variables:
Intangible character
Growth
Moderating effect:
Experience
H1a
H1c, H2b
H1b, H2a
H3
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Table 1. Variables and measurements 
Variable Measurement 
R&D innovation type 
(R&Di) 
Dummy variable (1 if R&D and 0 otherwise) 
Product innovation type 
(PDIi) 
Dummy variable (1 if Product innovation and 0 otherwise) 
Process innovation 
type(PCIi) 
Dummy variable (1 if Process innovation and 0 otherwise) 
Firm value (abnormal 
returns: ARi) 
See equation 2 
Firm growth (Gri) Growth=1/3·[ln(turnovert-1/ turnovert-3)]. 
Experience (Expi) Age of the firm 
Intangible character (Inti) Dummy variable (1 if the firm includes service components and 0 if it is a 
pure manufacturer) 
 
 
 
Table 2. Effect of innovation-related activities on firm value 
Event 
window 
Garch Abnormal 
Returns 
Brown and 
Warner’s test 
Theil Abnormal 
Returns 
Brown and 
Warner’s test 
-1 0.00546 2.278 0.00545 2.472 
0 -0.00350 -0.780 -0.00162 -0.371 
+1 -0.00357 -0.953 -0.00441 -0.971 
 
 
Table 3. Effect of innovation types on excess returns 
Variable Parameters from Garch abnormal returns 
Parameters from 
Theil abnormal returns 
Product innovation -0.138
* 
(0.049) 
-0.141* 
(0.049) 
Process innovation -0.109
* 
(0.046) 
-0.118* 
(0.046) 
Product innovation x experience 0.002
* 
(0.0007) 
0.002* 
(0.0007) 
Process innovation x experience 0.001
* 
(0.0008) 
0.001* 
(0.0008) 
Experience -0.002
* 
(0.0007) 
-0.002* 
(0.0007) 
Intangible carácter -0.043
* 
(0.017) 
-0.043* 
(0.017) 
Growth 
 
0.016 
(0.008) 
0.010 
(0.008) 
Constant 0.141
* 
(0.050) 
0.144* 
(0.050) 
R-squared 0.420 0.446 
*=p<0.05 
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Table 4. Main results of the hypotheses tested 
Hypothesis Result 
H.1a.: R&D leads to an increase in firm value. 
 
Accept 
H.1b.: Product innovation leads to an increase in firm value. 
 
Accept 
H.1c.: Process innovation lead to an increase in firm value. 
 
Accept 
H.2a.: R&D (as a promise of future tangible items) has an effect on 
firm value which is different from product innovations (which is 
already tangible). 
 
Accept 
H.2b.: R&D (as a promise of future tangible items) has an effect on 
firm value which is different from process innovations (which is 
already tangible). 
 
Accept 
H.3.: Firm’s experience exerts a moderator effect on the impact of 
innovation on firm value. 
Accept 
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